Refractory Seizures
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. (NCT05064878) | Zogenix, Inc. | 2022-03-08 |
Track Refractory Seizures automatically
Every clearance here is in the API, with alerts when new ones post.